Dr. Joseph Gabriele reports

DELIVRA SUCCESSFULLY DEMONSTRATES TARGETED PAIN RELIEF WITH TOPICAL IBUPROFEN

Delivra Corp. has demonstrated the ability to treat pain directly with a topical version of Advil (ibuprofen). Testing for effects on joint pain and inflammation, topical Delivra-ibuprofen formulation offers long-term pain and swelling reduction compared with oral ibuprofen.

In preclinical testing, undertaken by an independent third party research organization, the Delivra-ibuprofen formulation provided sustained pain reduction. In the study, Delivra-ibuprofen was tested in an acute canine model of arthritis where the formulation performed equally or better for swelling and pain reduction compared with its oral equivalent and test controls. This exemplifies Delivra's technology, with its multilayer liposomal system, is capable of gradually releasing the active ingredient to the area of need. This transdermal slow release is a valuable and highly advantageous characteristic of the topical Delivra-ibuprofen cream and may offer significant advantages over oral medication, with better localization of the drug at the site of need, yielding quicker and longer lasting relief.

"This impressive preclinical data further validates Delivra's platform technology by outperforming both oral delivery and a leading transdermal base, and offering patients an effective, safe and convenient cream for pain. With a robust pharmaceutical pipeline of high-value innovative products, Delivra-ibuprofen formulation promises a unique commercialization opportunity. As such, we, will continue to pursue out-licensing opportunities for major global markets to unlock the value of our portfolio," said Dr. Joseph Gabriele, chief executive officer of Delivra.

Delivra's research and development includes pharmaceutical formulations, compounding, stability testing, and measurement of localized penetration and delivery of drugs including ibuprofen. The company is advancing this Delivra-ibuprofen formulation as the patent-pending technology entitled "Transdermal formulations for delivery of propionic and acetic acid NSAIDs and their use in the treatment of NSAID-responsive diseases and conditions."

Delivra has filed a provisional U.S. patent to protect its unique formulation and it is currently available by prescription across Canada through the compound pharmacy services of NKS Health Ltd.

About Delivra Corp.

Delivra is a specialty biotechnology company having a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules through the skin, in a targeted manner. Delivra manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivRelief brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and under the LivSport brand for sports performance. LivRelief products are available in pharmacies, grocery chains and independent health food stores across Canada, including, but not limited to, Shoppers Drug Mart, Walmart, Loblaw, Rexall, Pharmasave, London Drugs, and on-line at the LivRelief website. In parallel with its consumer products business, Delivra also has a mandate to license its patent-pending, proprietary transdermal delivery technology platform to pharmaceutical companies globally, for the repurposing of pharmaceutical molecules transdermally to treat a broad range of conditions, along with licensing its over-the-counter products globally.

We seek Safe Harbor.